Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2α-isoprostane levels in postmenopausal women

We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2α-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2α-isoprostanes after 3 or 6 months of treatment.